On July 17, Cencora rose 3.25% in pre-market trading, trading at $318.0/share with turnover of $5.4 million, as multiple positive catalysts continued to drive sentiment.

On the news front, Evercore ISI raised its price target on Cencora to $330 from $300 on July 7, maintaining an Outperform rating. The analyst consensus mean target stands at $353.50 according to FactSet. Additionally, Chairman Mark Durcan purchased 4,000 shares at $266 apiece for approximately $1 million — his largest transaction during his board tenure, described as an unusually large insider buy following the stock's decline after Q2 earnings. The company also announced resumption of its share repurchase program with authorization of up to $2 billion after pausing it in January. Furthermore, Cencora signed a distribution agreement with Gilead's Kite unit to support FDA-approved CAR-T cell therapies Yescarta and Tecartus in the U.S. market, expanding its specialty pharmaceutical distribution capabilities.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)